Published 2019
| Version v1
Publication
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis
- Creators
- Balleari E.
- FILIBERTI, ROSA ANGELA
- SALVETTI, CLAUDIA
- Allione B.
- Angelucci E.
- Bruzzone M.
- Calzamiglia T.
- Cavaliere M.
- Cavalleri M.
- Cilloni D.
- Clavio M.
- Crisa E.
- Da Col A.
- Danise P.
- Pilo F.
- FERRERO, DARIO
- Finelli C.
- GIOIA, DOMENICO
- Lemoli R. M.
- Masiera E.
- Messa E.
- Miglino M.
- Musto P.
- Natalie Oliva E.
- Poloni A.
- Salvi F.
- Sanna A.
- Scudeletti M.
- Tassara R.
- Santini V.
- Others:
- Balleari, E.
- Filiberti, ROSA ANGELA
- Salvetti, Claudia
- Allione, B.
- Angelucci, E.
- Bruzzone, M.
- Calzamiglia, T.
- Cavaliere, M.
- Cavalleri, M.
- Cilloni, D.
- Clavio, M.
- Crisa, E.
- Da Col, A.
- Danise, P.
- Pilo, F.
- Ferrero, Dario
- Finelli, C.
- Gioia, Domenico
- Lemoli, R. M.
- Masiera, E.
- Messa, E.
- Miglino, M.
- Musto, P.
- Natalie Oliva, E.
- Poloni, A.
- Salvi, F.
- Sanna, A.
- Scudeletti, M.
- Tassara, R.
- Santini, V.
Description
Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking.
Additional details
- URL
- http://hdl.handle.net/11567/987749
- URN
- urn:oai:iris.unige.it:11567/987749
- Origin repository
- UNIGE